SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells - Liang, Yang; Tebaldi, Toma; Rejeski, Kai; Joshi, Poorval; Stefani, Giovanni; Taylor, Ashley; Song, Yuanbin; Vasic, Radovan; Maziarz, Jamie; Balasubramanian, Kunthavai; Ardasheva, Anastasia; Ding, Alicia; et al. (Leukemia, 2018)
Keywords: 38; 38/39; 38/90; 38/91; 45; 631/80; 692/699/1541/1990/1673; Alternative splicing; Backup software; Binding sites; Cancer; Cancer Research; Carcinogenesis; Care and treatment; Critical Care Medicine; Development and progression; Exons; Gene mutation; Genetic aspects; Health aspects; Hematology; Hematopoiesis; In vivo methods and tests; Intensive; Internal Medicine; Medical schools; Medicine; Medicine & Public Health; Messenger RNA; mRNA; Mutation; Myelodysplastic syndrome; Myelodysplastic syndromes; Oncology; Phenotypes; Proteins; Ribonucleic acid; RNA; RNA processing; RNA splicing; Splicing factors; Tumorigenesis